Heron Therapeutics Analyst Ratings
Heron Therapeutics Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/15/2023 | 231.13% | Needham | → $5 | Reiterates | Buy → Buy |
07/25/2023 | 231.13% | Needham | $6 → $5 | Maintains | Buy |
05/12/2023 | 297.35% | Needham | $7 → $6 | Maintains | Buy |
04/21/2023 | 363.58% | Needham | → $7 | Reiterates | → Buy |
03/24/2023 | 562.25% | Evercore ISI Group | $15 → $10 | Maintains | Outperform |
03/24/2023 | 363.58% | Needham | $8 → $7 | Maintains | Buy |
11/09/2022 | 429.8% | Needham | $10 → $8 | Maintains | Buy |
06/30/2022 | 562.25% | Needham | $14 → $10 | Maintains | Buy |
05/10/2022 | 827.15% | Needham | $16 → $14 | Maintains | Buy |
12/02/2020 | 1489.4% | SVB Leerink | $21 → $24 | Maintains | Outperform |
05/27/2020 | 1489.4% | Guggenheim | → $24 | Initiates Coverage On | → Buy |
03/02/2020 | 2813.91% | Needham | $48 → $44 | Maintains | Buy |
02/20/2020 | 3078.81% | Needham | $50 → $48 | Maintains | Buy |
10/03/2019 | 2019.21% | JMP Securities | $38 → $32 | Reiterates | → Market Outperform |
09/14/2018 | 3542.38% | Stifel | → $55 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
---|---|---|---|---|---|
2023年08月15日 | 231.13% | 李約瑟 | →$5 | 重申 | 購買→購買 |
07/25/2023 | 231.13% | 李約瑟 | $6→$5 | 維護 | 買 |
2023年05月12日 | 297.35% | 李約瑟 | $7→$6 | 維護 | 買 |
04/21/2023 | 363.58% | 李約瑟 | →$7 | 重申 | →購買 |
03/24/2023 | 562.25% | Evercore ISI集團 | $15→$10 | 維護 | 跑贏大盤 |
03/24/2023 | 363.58% | 李約瑟 | $8→$7 | 維護 | 買 |
11/09/2022 | 429.8% | 李約瑟 | $10→$8 | 維護 | 買 |
2022/06/30 | 562.25% | 李約瑟 | $14→$10 | 維護 | 買 |
2022年05月10日 | 827.15% | 李約瑟 | $16→$14 | 維護 | 買 |
12/02/2020 | 1489.4% | SVB Leerink | $21→$24 | 維護 | 跑贏大盤 |
05/27/2020 | 1489.4% | 古根海姆 | →$24 | 開始承保 | →購買 |
03/02/2020 | 2813.91% | 李約瑟 | $48→$44 | 維護 | 買 |
02/20/2020 | 3078.81% | 李約瑟 | $50→$48 | 維護 | 買 |
2019年10月03日 | 2019.21% | JMP證券 | $38→$32 | 重申 | →市場跑贏大盤 |
2018年09月14日 | 3542.38% | Stifel | →$55 | 開始承保 | →購買 |
What is the target price for Heron Therapeutics (HRTX)?
蒼鷺治療公司(HRTX)的目標價格是多少?
The latest price target for Heron Therapeutics (NASDAQ: HRTX) was reported by Needham on August 15, 2023. The analyst firm set a price target for $5.00 expecting HRTX to rise to within 12 months (a possible 231.13% upside). 7 analyst firms have reported ratings in the last year.
Needham於2023年8月15日報道了蒼鷺治療公司(納斯達克代碼:HRTX)的最新目標價。這家分析公司將目標價定為5美元,預計HRTX將在12個月內上漲至(可能上漲231.13%)。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Heron Therapeutics (HRTX)?
蒼鷺治療公司(HRTX)的最新分析師評級是多少?
The latest analyst rating for Heron Therapeutics (NASDAQ: HRTX) was provided by Needham, and Heron Therapeutics reiterated their buy rating.
Needham提供了對蒼鷺治療公司(納斯達克代碼:HRTX)的最新分析師評級,蒼鷺治療公司重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Heron Therapeutics (HRTX)?
蒼鷺治療公司(HRTX)的下一次分析師評級將於何時發佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Heron Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Heron Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.
分析師在進行了廣泛的研究後得出了股票評級,其中包括查閱公共財務報表,與蒼鷺治療公司的高管和客戶交談,以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。蒼鷺治療的最後一次評級是在2023年8月15日提交的,所以你應該預計下一次評級將在2024年8月15日左右提供。
Is the Analyst Rating Heron Therapeutics (HRTX) correct?
分析師對蒼鷺治療公司(HRTX)的評級正確嗎?
While ratings are subjective and will change, the latest Heron Therapeutics (HRTX) rating was a reiterated with a price target of $0.00 to $5.00. The current price Heron Therapeutics (HRTX) is trading at is $1.51, which is within the analyst's predicted range.
雖然評級是主觀的,並將發生變化,但最新的蒼鷺治療公司(HRTX)的評級被重申,目標價在0.00美元到5.00美元之間。蒼鷺治療公司(HRTX)目前的交易價格為1.51美元,在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。